Leeward Financial Partners LLC Boosts Stake in Eli Lilly and Company (NYSE:LLY)

Leeward Financial Partners LLC raised its holdings in Eli Lilly and Company (NYSE:LLY) by 51.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 6,422 shares of the company’s stock after acquiring an additional 2,195 shares during the quarter. Eli Lilly and Company accounts for about 1.8% of Leeward Financial Partners LLC’s holdings, making the stock its 17th biggest position. Leeward Financial Partners LLC’s holdings in Eli Lilly and Company were worth $4,958,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in LLY. Landscape Capital Management L.L.C. grew its position in Eli Lilly and Company by 200.9% during the fourth quarter. Landscape Capital Management L.L.C. now owns 4,919 shares of the company’s stock worth $3,797,000 after buying an additional 3,284 shares during the period. PAX Financial Group LLC raised its holdings in Eli Lilly and Company by 19.6% during the fourth quarter. PAX Financial Group LLC now owns 1,020 shares of the company’s stock worth $787,000 after purchasing an additional 167 shares during the last quarter. Astra Wealth Partners LLC purchased a new stake in Eli Lilly and Company during the fourth quarter worth $202,000. Wescott Financial Advisory Group LLC grew its holdings in Eli Lilly and Company by 1.1% in the fourth quarter. Wescott Financial Advisory Group LLC now owns 9,381 shares of the company’s stock valued at $7,242,000 after purchasing an additional 98 shares during the last quarter. Finally, Thoroughbred Financial Services LLC increased its position in shares of Eli Lilly and Company by 7.7% in the fourth quarter. Thoroughbred Financial Services LLC now owns 20,792 shares of the company’s stock valued at $16,051,000 after buying an additional 1,487 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on LLY. StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Morgan Stanley set a $1,146.00 target price on Eli Lilly and Company in a research note on Thursday, March 6th. Truist Financial lifted their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd. Wells Fargo & Company increased their price target on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. Finally, Bank of America reaffirmed a “buy” rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,009.72.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $788.62 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The firm’s 50-day moving average price is $849.30 and its two-hundred day moving average price is $833.74. The stock has a market capitalization of $747.75 billion, a P/E ratio of 67.35, a P/E/G ratio of 1.40 and a beta of 0.34. Eli Lilly and Company has a 52-week low of $711.40 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company declared that its Board of Directors has initiated a share buyback plan on Monday, December 9th that authorizes the company to repurchase $15.00 billion in shares. This repurchase authorization authorizes the company to reacquire up to 2% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.